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clinical peanut allergy. In equivocal cases, oral food challenges
(OFCs) are required. However, OFCs are laborious and not
without risk; thus, a test that could accurately diagnose peanut
allergy and reduce the need for OFCs is desirable.
Objective: To assess the performance of basophil activation test
(BAT) as a diagnostic marker for peanut allergy.
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http://dx.doi.org/10.1016/j.jaci.2014.04.039IgE (sIgE) to peanut and its components. BAT was performed
using flow cytometry, and its diagnostic performance was
evaluated in relation to allergy versus tolerance to peanut and
validated in an independent population (n 5 65).
Results: BAT in peanut-allergic children showed a peanut
dose-dependent upregulation of CD63 and CD203c while there
was no significant response to peanut in peanut-sensitized but
tolerant (P < .001) and non–peanut-sensitized nonallergic
children (P < .001). BAT optimal diagnostic cutoffs showed 97%
accuracy, 95% positive predictive value, and 98% negative
predictive value. BAT allowed reducing the number of required
OFCs by two-thirds. BAT proved particularly useful in cases in
which specialists could not accurately diagnose peanut allergy
with SPT and sIgE to peanut and to Arah2. Using a 2-step
diagnostic approach in which BAT was performed only after
equivocal SPT or Arah2-sIgE, BAT had a major effect (97%
reduction) on the number of OFCs required.
Conclusions: BAT proved to be superior to other diagnostic
tests in discriminating between peanut allergy and
tolerance, particularly in difficult cases, and reduced the need
for OFCs. (J Allergy Clin Immunol 2014;134:645-52.)
Key words: Anaphylaxis, basophil activation test, CD203c, CD63,
diagnosis, flow cytometry, food allergy, peanut allergy, ROC curve
Ten percent of North American children are sensitized to
peanut,1 but only 1.4% are clinically allergic to peanut.2 The gold
standard for the diagnosis of peanut allergy is double-blind
placebo-controlled food challenge (DBPCFC); however, this is
time-consuming and carries the risk of causing an acute allergic
reaction.3 Therefore, in clinical practice, whenever possible, the
diagnosis of peanut allergy is based on the combination of a his-
tory of an immediate-type allergic reaction to peanut together
with in vivo or in vitro measurement of sensitization.4 Some
clinics use peanut-specific IgE (P-sIgE) alone, others use peanut
skin prick test (SPT) alone, and some such as ours use a combina-
tion of these tests. No clear consensus exists as towhich is the best
approach. The diagnosis of peanut allergy can be particularly
difficult in cases in which there is no clear history of peanut con-
sumption. With increasing awareness about food allergy and the
fact that many families avoid peanut in the first few years of
life, peanut-sensitized children with no history of oral exposure
to peanut constitute a considerable proportion of patients seen
in allergy clinics. This has resulted in a marked increase in the
number of oral food challenge (OFC) requests. Thus, a test that
could accurately diagnose peanut allergy reducing the need for
OFC is desirable and would change clinical practice.645
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646 SANTOS ET ALAbbreviations usedBAT: Basophil activation testCRD: Component-resolved diagnosisDBPCFC: Double-blind placebo-controlled food challengefMLP: Formyl-methionyl-leucyl-phenylalanineNA: Non–peanut-sensitized nonallergicOFC: Oral food challengePA: Peanut-allergicPPV: Positive predictive valuePS: Peanut-sensitized but tolerantP-sIgE: Peanut-specific IgEROC: Receiver-operating characteristicsIgE: Specific IgESPT: Skin prick testTo try to improve the utility of SPT and P-sIgE, diagnostic
decision values have been determined.5-9 However, a large
proportion of peanut-sensitized children have SPT and P-sIgE
results below these cutoffs, falling in the immunologic gray area10
(see Fig E1 in this article’s Online Repository at www.jacionline.
org). Ara h 2 is a dominant allergen and has been proved to be partic-
ularly useful for diagnosis11,12; however, peanut allergy can develop
inpatientswith undetectable specific IgE (sIgE) levels toAra h 2 and
other major peanut allergens.12-14
The basophil activation test (BAT) to peanut is an in vitro assay
in which the expression of activationmarkers on the surface of ba-
sophils is evaluated by using flow cytometry after stimulation
with peanut allergens.15,16 It can be performed using 1 mL of
blood without requiring cell separation. We sought to assess the
performance of BAT in the diagnosis of peanut allergy and to
compare it with existing diagnostic tests.
METHODS
Study population
Peanut-allergic (PA), peanut-sensitized but tolerant (PS), and non–peanut-
sensitized nonallergic (NA) children were prospectively and consecutively
enrolled from our Pediatric Allergy service on the days when the investigator
(A.F.S.) was available to perform BAT. The allergic status to peanut was
determined by usingOFCs, except for (1) childrenwith a convincing history of
systemic reaction(s) to peanut within 1 year of their visit and (a) wheal size of
SPTof 8mmormore8 and/or (b) P-sIgE level of 15KUA/L ormore,
8 whowere
considered peanut allergic; and (2) children (15NA and 5 PS)whowere able to
eat 4 g or more of peanut protein twice a week (as assessed by a validated pea-
nut consumption questionnaire17) without developing allergic symptoms, who
were considered peanut tolerant. Peanut sensitization was defined by a wheal
size of SPT of 1 mm or more and/or P-sIgE level of 0.10 KUA/L or more.
All children underwent clinical evaluation, SPT, P-sIgE determination,
component-resolved diagnosis (CRD), and OFC, as appropriate. An additional
sampleofbloodwasdrawn in lithiumheparin (BDVacutainer, Plymouth,United
Kingdom) for BAT, which was performed within 4 hours of blood collection.
The study was approved by the South East London Research Ethics Committee
2, and written informed consent was obtained from parents of all children.
Skin prick testing, serum-sIgE, and OFCs
SPT was performed using peanut extract (ALK-Abello, Hørsholm,
Denmark), as previously described.18 The level of sIgE (peanut and CRD)
was measured using an immunoenzymatic assay (ImmunoCAP, Thermo-
Fisher, Uppsala, Sweden).
DBPCFC consisted of 6 verum doses and 3 placebo doses randomly
interspersed with verum doses up to a cumulative dose of 9.35 g of peanut
protein (see Table E1 in this article’s Online Repository at www.jacionline.org). Children of 1 to 3 years were given 1 placebo and 5 verum doses up to
a cumulative dose of 4.35 g of peanut protein. In infants (<_1 year), the OFCs
were open up to a cumulative dose of 4.35 g of peanut protein. Nine older chil-
dren also received an open OFC for logistical reasons. OFCs were considered
negativewhen all doses were tolerated. If an allergic reaction developed at any
stage after a verum dose, the OFCwas considered positive (see Table E2 in this
article’s Online Repository at www.jacionline.org) and the symptoms treated.
If a reaction followed a placebo dose, the patient was brought in for 2-day chal-
lenge (1 day placebo and 1 day verum).19
Basophil activation test
Heparinized whole blood was stimulated for 30 minutes at 378C with
peanut extract (ALK Abello) diluted in RPMI medium (GIBCO, Paisley,
United Kingdom) at serial 10-fold dilutions from 10 mg/mL to 0.1 ng/mL. For
details about the extract and allergen concentrations, see this article’s Online
Repository at www.jacionline.org.20 Polyclonal goat antihuman IgE (1 mg/
mL, Sigma-Aldrich, Poole, United Kingdom), monoclonal mouse antihuman
Fc 3RI (2.5 mg/mL, eBioscience, San Diego, Calif), formyl-methionyl-leucyl-
phenylalanine (fMLP, 1 mM, Sigma-Aldrich), or RPMI medium alone
were used as controls. Before erythrocyte lysis, cells were stained with
CD123-FITC (eBioscience), CD203c-PE, HLA-DR-PerCP, and CD63-APC
(Biolegend, San Diego, Calif). Basophils were gated as SSClow/CD203c1/
CD1231/HLA-DR2 (see Fig E2 in this article’s Online Repository at
www.jacionline.org). Basophil expression of CD63 and CD203c was
evaluated using FACS CantoII with FACSDiva software (BD Biosciences,
San Jose, Calif). The flow cytometry data were analyzed using FlowJo soft-
ware (version 7.6.1; TreeStar, Ashland, Ore) by an investigator who was
blinded to the clinical features of the participants. Basophil activation was ex-
pressed as %CD631 basophils and as the stimulation index of the mean fluo-
rescence intensity (MFI) of CD203c.
Statistical analysis
We estimated that a sample of 32 PA and 32 PS children would give us 99%
power, at a 2-sided type I error probability of 0.05, to detect a significant
difference in the %CD631 basophils after peanut stimulation between PA and
PS on the basis of data from a previous study.21
Qualitative variables were compared between PA and PS children using the
Fisher exact test or x2 tests, and continuous variables were compared using the
Mann-Whitney U test or the Kruskal-Wallis test.
The performance of allergy tests was examined against the allergic status to
peanut using receiver-operating characteristic (ROC)-curve analyses. The cutoffs
to predictpeanut allergy andpeanut tolerance forBATand thevarious allergy tests
with optimal accuracy were determined and validated. We performed internal
validation using repeated random subsampling validation (bootstrap) and ‘‘leave-
one-out’’ methodologies.22 Both methodologies produced similar results in esti-
mating the optimal cutoff points, and the former methodology is reported. The
95%CIwas constructed using bootstrappingmethodologywith 1000 replications
to reflect on the reproducibility.23Anexternalvalidation studywasalso conducted
usinganewcohort of 65 subjects (25PA,24PS, and16NA)mainly recruited from
the Peanut Allergy Sensitization study, a group of patients from all over the coun-
trywhowereexcluded from theLearningEarlyAboutPeanutAllergy study,18and
from a private Pediatric Allergy clinic in London. The cutoffs previously deter-
mined in the primary study population were applied to this validation study
population and sensitivity, specificity, predictive values, likelihood ratios, and ac-
curacy were calculated.
Three Pediatric Allergy specialist attending physicians were asked to
classify 44 equivocal cases from the primary study population as peanut
allergic or tolerant on the basis of history and results of SPT, P-sIgE, and CRD.
The agreement between physicians was calculated as percentages and
assessed with k statistics.24
Statistical analyses were performed with SPSS 20.0 and STATA 12.1 for
Windows. Significance was determined using a 2-sided a level of 0.05.
Combination of BAT with other diagnostic tests
In the primary study population, after ROC-curve analyses, we compared
the performance of BATwith SPT, P-sIgE, and Arah2-sIgE using conventional
TABLE I. Demographic and clinical features of the whole primary study population (n 5 104) and of the subgroup of the primary
study population with equivocal clinical history and inconclusive SPT and sIgE results (n 5 44)
Characteristic
Primary study population (n 5 104)
Subpopulation with equivocal allergy
test results (n 5 44)
PA (n 5 43)
Peanut tolerant (n 5 61)
P value* PA (n 5 8) PS (n 5 36) P valuePS (n 5 36) NA (n 5 25)
Age (y) 5.5 (1.5-17.0) 4.0 (0.5-13.0) 5.0 (0.8-13.5) .005 5.0 (2.0-6.0) 4.0 (0.5-13.0) .964
Males 32 (74.4) 23 (63.9) 18 (72.0) .366 4 (50.0) 23 (63.9) .690
History of oral exposure
to peanut
26 (60.5) 7 (19.4) 15 (60.0) <.001 0 (0) 7 (19.5) .618
SPT to peanut (mm) 9 (2-19) 2 (0-12) 0 (0-0) <.001 7 (2-9) 2 (0-12) .002
sIgE to peanut (KUA/L) 14.50 (0.14-604.0) 0.81 (0.01-35.70) 0.01 (0-0.08) <.001 0.94 (0.14-14.50) 0.81 (0.01-35.70) .964
sIgE to Ara h 1 (KUA/L) 0.45 (0-199.0) 0.06 (0-3.79) 0.01 (0-0.03) .001 0.03 (0.01-8.67) 0.06 (0-3.79) .622
sIgE to Ara h 2 (KUA/L) 9.21 (0.05-386.0) 0.06 (0.01-1.84) 0.01 (0-0.08) <.001 0.15 (0.05-8.95) 0.06 (0.01-1.84) .023
sIgE to Ara h 3 (KUA/L) 0.06 (0-89.60) 0.05 (0-1.36) 0.01 (0-0.04) .217 0.01 (0.01-1.62) 0.05 (0-1.36) .189
sIgE to Ara h 8 (KUA/L) 0.08 (0-57.80) 0.01 (0-35.80) 0.01 (0-0.02) .027 0.01 (0.01-4.66) 0.01 (0-35.80) .893
sIgE to Ara h 9 (KUA/L) 0.01 (0-5.62) 0.02 (0-11.0) 0.01 (0-0.02) .602 0.01 (0.01-0.28) 0.02 (0-11.0) .823
Other food allergy 39 (90.7) 32 (88.9) 3 (12.0) 1.0 8 (100) 32 (88.9) 1.0
Atopic eczema 36 (83.7) 21 (58.3) 12 (48.0) .022 5 (62.5) 21 (58.3) 1.0
Asthma 13 (30.2) 6 (16.7) 0 (0) .193 0 (0) 6 (16.7) .573
Allergic rhinitis 14 (32.6) 9 (25.0) 2 (8.0) .620 0 (0) 9 (25.0) .175
Pollen allergy 14 (32.6) 8 (22.2) 1 (4.0) .349 0 (0) 8 (22.2) .284
Nonatopic 0 (0) 0 (0) 12 (48.0) — 0 (0) 0 (0) —
Values are expressed as no. (%) or median (range).
*P value refers to the comparison between PA and PS patients.
P < .05.
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ered in combination with other allergy tests, that is, considering the results
of different tests simultaneously, and when considered as a second or third
step in the diagnostic process, that is, performed in selected patients in
whom the results of single or of combinations of tests were equivocal.
When interpreted individually, the results of standard allergy tests were
considered diagnostic of allergy when the positive predictive value cutoff was
95% or more, diagnostic of tolerance when the negative predictive value
(NPV) cutoff was less than 95%, and equivocal when between the positive and
the negative cutoffs (Fig E1). For BAT, we used the cutoff for the mean of
%CD631 basophils at 10 and 100 ng/mL of peanut extract and considered
BAT equivocal in the case of ‘‘nonresponders’’ (defined as <5% CD631 baso-
phils to IgE-mediated controls and >_5% CD63%1 basophils to fMLP).
The combination of allergy tests was interpreted as equivocal if one test
result was 95% or more PPV cutoff and another test result was less than 95%
NPV cutoff or when all tests gave equivocal results (as defined above) or a
combination of equivocal results and results less than 95% NPV.
In these simulations, OFCs were deemed required when the interpretation
of tests was equivocal. The combination of SPT and P-sIgE was the clinical
reference point against which the change in the number of OFCs required was
determined.RESULTS
Study participants
One hundred nine children, 76% boys, aged from 5 months to
17 years (median, 5 years), participated in the study (see Fig E3 in
this article’s Online Repository at www.jacionline.org). Sixty-six
OFCs to peanut were performed: 20 positive, 41 negative, and 5
indeterminate (3 patients refused to eat and 2 showed subjective
symptoms in the absence of objective signs). These 5 patients
were excluded. Among the study participants (n 5 104, 43 PA
and 61 peanut-tolerant), 48 patients underwent DBPCFC and 13
open OFCs. Demographic and clinical features of the study
population are represented in Table I and in Figs E4 and E5 in
this article’s Online Repository at www.jacionline.org.BAT discriminates between allergic and tolerant
children
The basophils of 12 (11.5%) children were ‘‘nonresponders’’
andwere necessarily excluded from the comparison of BATresults
between groups and from the ROC-curve analysis; however, they
were taken into account when assessing the clinical application of
BAT and its effect in the reduction of OFCs.
In PA children, basophils showed increased expression of
CD63 and CD203c, with increasing concentrations of peanut
extract up to 100 ng/mL followed by a plateau. The basophils
from PS children did not significantly respond to peanut
(P <.001 for the comparison of the median basophil activation be-
tween PA and PS patients) neither did basophils fromNA children
(Fig 1; see Fig E6 in this article’s Online Repository at www.
jacionline.org). This difference in basophil response between
groups was reflected in other parameters of BAT (see Table E3
in this article’s Online Repository at www.jacionline.org). The
%CD631 basophils in response to the negative control (P 5
.958) and non–IgE-mediated positive control (fMLP, P 5 .581)
was similar across groups. The proportion of nonresponders
was higher in peanut-tolerant (including PS and NA) than in
peanut-allergic (P 5 .012) children. Similar findings were
observed for the stimulation index of CD203c.Diagnostic cutoff values
Peanut allergy (based on OFCs or 95% PPV, n 5 42) and
tolerance status (based on OFCs or consumption, n5 50) was the
reference point to evaluate the diagnostic performance of BATon
ROC-curve analysis (Table E3).
The best diagnostic cutoff values (although all cutoffs
performed well without statistically significant differences be-
tween them) were obtained for %CD631 basophils at 100 ng/mL
and mean %CD631 basophils at 10 and 100 ng/mL of peanut
extract (Table II). These were simultaneously optimal, negative,
FIG 1. BAT to peanut in PA (n 5 42, A), PS (n5 31, B), and NA (n5 19, C) children. The P value refers to the
comparison of the median %CD631 basophils at selected doses between PA and PS patients: ***P < .001,
**P < .01, and ns, nonsignificant. 0 represents the negative control, and anti-IgE and fMLP are the positive
controls.
TABLE II. Optimal cutoffs for the parameters of BAT to peanut with the largest area under the ROC curve (n 5 92)
BAT
parameters Cutoff AUC ROC Sensitivity (%) Specificity (%) PPV (%) NPV (%) LR1 LR2
Diagnostic
accuracy (%)
%CD631
peanut extract
100 ng/mL
8.11
(2.93-16.47)
0.97
(0.93-1.0)
97.6
(87.4-99.9)
96.0
(86.3-99.5)
95.3
(84.2-99.4)
98.0
(89.1-99.9)
24.4
(6.3-95.0)
0.02
(0.0-0.17)
96.7
(93.1-100)
SI CD203c
peanut extract
100 ng/mL
1.88
(1.62-2.24)
0.96
(0.91-1.0)
95.2
(83.8-99.4)
96.0
(86.3-99.5)
95.2
(83.8-99.4)
96.0
(86.3-99.5)
23.8
(6.1-92.7)
0.05
(0.01-0.19)
95.7
(91.5-99.8)
Mean %CD631
peanut extract
10-100 ng/mL
4.78
(4.78-11.76)
0.97
(0.93-1.0)
97.6
(87.4-99.9)
96.0
(86.3-99.5)
95.3
(84.2-99.4)
98.0
(89.1-99.9)
24.4
(6.3-95.0)
0.02
(0.0-0.17)
96.7
(93.1-100)
Mean SI CD203c
peanut extract
10-100 ng/mL
1.40
(1.40-1.75)
0.97
(0.94-1.0)
100.0
(91.6-100)
94.0
(83.5-98.7)
93.3
(81.7-98.6)
100.0
(92.5-100)
16.7
(5.6-49.9)
—* 96.7
(93.1-100)
Values in parentheses represent 95% CI.
AUC, Area under the ROC curve; LR1, positive likelihood ratio; LR2, negative likelihood ratio; MFI, mean fluorescence intensity; %CD631, percentage of CD63-positive
basophils (corrected for the negative control); SI CD203c, stimulation index of CD203c (MFI CD203c poststimulation/MFI CD203c of negative control).
*LR2 could not be determined because sensitivity was 100%.
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95% PPV, 98% NPV, and 97% accuracy. See Table E4 in this
article’s Online Repository at www.jacionline.org for optimal
cutoffs for other BAT parameters.
The area under the ROC curve for BATwas superior to that for
other allergy tests (Fig 2, A; see Table E5 in this article’s Online
Repository at www.jacionline.org). Arah2-sIgE performed better
than did sIgE to other peanut components (see Fig E7 in this
article’s Online Repository at www.jacionline.org).
Validation of diagnostic cutoff values in an
independent population
To externally validate our findings, we prospectively
recruited 65 children (25 PA, 24 PS, and 16 NA; see Table
E6 in this article’s Online Repository at www.jacionline.org)
who underwent the same study procedures as the primary
study population. The vast majority (94%) underwent OFCs,
and all positive OFCs were DBPCFC. Applying the optimal
cutoff previously determined for the mean of %CD631 baso-
phils at 10 and 100 ng/mL of peanut extract, BAT showed
100% specificity, 83.3% sensitivity, 100% PPV, 90.2% NPV,
and 93.4% accuracy and was superior to SPT, sIgE, and
Arah2-sIgE (see Table E7 in this article’s Online Repository
at www.jacionline.org).The use of BAT in peanut-sensitized children with
equivocal diagnosis
The utility of BAT was further assessed in the subgroup
(n 5 44) of the primary study population with equivocal history
and inconclusive results of SPT, P-sIgE, and CRD (Table I and
Fig 2, B).
Three Pediatric Allergy specialist attending physicians were
asked to classify them as peanut allergic or tolerant on the basis of
available information. In most of the cases (46% to 64%), the
physicians could not decide without doing an OFC. They
correctly diagnosed 26% to 36% and misclassified 9% to 16%
of the cases (14% false negatives). Agreement between the 3 pairs
of physicians was poor to fair, with k values of 0.16, 0.29, and
0.36. The 3 specialists agreed in 16 (36%) cases: 4 correctly
diagnosed, 1 misclassified, and in 11 cases they were unable to
decide. In contrast, BAT provided 36 (82%) correct diagnoses, 2
(5%) false positives, and 1 (2%) false negative and required 5
(11%) OFCs. Excluding nonresponders, BAT had a diagnostic
accuracy of 95% (Table E5).The combination of BAT with other diagnostic tests
We evaluated the diagnostic performance of different tests in
the primary study population (n 5 104), including BAT
FIG 2. ROC curves for BAT (red), SPT (blue), P-sIgE (green), and sIgE to Ara h 2 (orange) for the whole study
population (n 5 92) (A) and children with equivocal history, SPT, and sIgE to peanut and its components
(n 5 39) (B). For BAT, the average between %CD631 basophils at 10 and 100 ng/mL of peanut extract was
considered. For area under the ROC curves for different tests in the 2 study populations, see Table E5.
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own; considering the results of different diagnostic tests
simultaneously; and considering BAT as a second or third
sequential step in the diagnostic process, performed in patients
in whom the results of single or combinations of standard allergy
tests were equivocal.
Considering single tests, BAT performed best and allowed a
reduction in the number of OFCs by two-thirds, followed by
Arah2-sIgE and SPT. P-sIgE on its own performed the poorest,
conferring the highest number of OFCs and correctly diagnosing
only 55% of the patients. Considering combinations of allergy
tests, it was best to combine 2 different tests as opposed to 3 or 4
tests. All combinations of tests required an increase between 2-
and 3.5-fold in the number of OFCs compared with BAT alone.
With a view to apply BAT in clinical practice, we assessed the
role of BAT as a second or third step in the diagnostic workup,
which would require a smaller number of BATs (Table III; see
Fig E8 in this article’s Online Repository at www.jacionline.
org). The 2-step strategy significantly reduced the number of
OFCs, more than using Arah2-sIgE as a second step to SPT or
to P-sIgE (see Table E8 in this article’s Online Repository at
www.jacionline.org), as proposed by Dang et al.12 The 3-step
sequential strategy of SPT/Arah2-sIgE/BAT (Table III and
Fig E8) further reduced the number of OFCs to zero at the expense
of a slightly higher number of false-negative results (n 5 3).DISCUSSION
To arrive at a correct diagnosis of peanut allergy or tolerance, a
considerable proportion of peanut-sensitized patients seen in
allergy clinics need to undergo an OFC. Specialized centers have
become overwhelmed with the increasing number of OFC
requests, and overdiagnosis of peanut allergy due to overreliance
on allergy tests alone is common. There is a large immunologicalgray area between 95% PPV and 95% NPV cutoffs for SPT,
P-sIgE, and Arah2-sIgE (Fig E1). If we apply a single cutoff value
based on the ROC-curve point-of-inflexion, the diagnostic
accuracy of these tests suffers. In BAT, the ROC-curve optimal
cutoff acted simultaneously as positive and negative cutoff with
no immunologic gray area, allowing for a significant reduction
in the number of OFCs, even among difficult patients with con-
flicting history and results of SPT, P-sIgE, and CRD. Unlike for
these tests, for BAT, we were able to use the ROC-curve point-
of-inflexion as a single cutoff value while maintaining a 97%
diagnostic accuracy.
Our study is the largest study assessing the role of BAT in the
diagnosis of peanut allergy.21,25,26 It is the first study to prospec-
tively validate BAT in an independent population and to evaluate
its diagnostic performance on its own, in combination and
sequentially with other allergy tests, as well as its effect on the
number of OFCs. We studied a large population, including not
only sensitized but also nonsensitized nonallergic patients.
Although peanut-induced basophil activation would not be
expected in the absence of P-sIgE, it was important to
demonstrate the specificity of BAT in NA patients. BAT
maintained its good performance in an independent population
prospectively recruited to validate the diagnostic cutoffs. In 44
children with evidence of sensitization and conflicting allergy
test results, 3 specialist doctors showed poor agreement and
were unable to decide in most of the cases whether they were
peanut allergic without doing an OFC, while BAT still performed
very well in this subgroup.
One of the strengths of our study is that participants were
carefully clinically phenotyped, the vast majority by OFCs. In the
primary study population, 23 patients were assumed to have
peanut allergy on the basis of SPT and/or P-sIgE of 95% or more
PPV cutoffs (previously validated in our patient population8) and
positive history. This is a potential weakness of the study;
TABLE III. Performance of allergy tests in the diagnosis of peanut allergy (N 5 104)
Single diagnostic test Correct diagnoses* No. of false positives No. of false negatives No. of BATs No. of OFCs
Change in the
no. of OFCy
SPT 78 (75) 1 (1) 1 (1) — 24 (23) 212 (233)
P-sIgE 57 (55) 3 (3) 3 (3) — 41 (39) 15 (113)
Ara h 2 82 (79) 1 (1) 2 (2) — 19 (18) 217 (246)
BAT 89 (86§) 2 (2) 1 (1) 104 (100) 12 (12) 224 (267)
Combination of diagnostic tests Correct diagnoses* No. of false positives No. of false negatives No. of BATs No. of OFCs
Change in the
no. of OFCsy
SPT 1 P-sIgE 67 (64) 1 (1) 0 (0) — 36 (35) 0 (0)
P-sIgE 1 Ara h 2 66 (63) 1 (1) 1 (1) — 36 (35) 0 (0)
P-sIgE 1 BAT 66 (63) 1 (1) 2 (2) 104 (100) 35 (34) 21 (23)
SPT 1 BAT 77 (74) 2 (2) 0 (0) 104 (100) 25 (25) 211 (231)
SPT 1 Ara h 2 78 (75) 1 (1) 0 (0) — 25 (24) 211 (231)
Ara h 2 1 BAT 77 (74) 1 (1) 2 (2) 104 (100) 24 (24) 212 (233)
SPT 1 P-sIgE 1 Ara h 2 67 (64) 1 (1) 0 (0) — 36 (35) 0 (0)
SPT 1 Ara h 2 1 BAT 70 (67) 1 (1) 0 (0) 104 (100) 33 (33) 23 (28)
SPT 1 P-sIgE 1 BAT 63 (61) 2 (2) 0 (0) 104 (100) 39 (38) 13 (18)
P-sIgE 1 Ara h 2 1 BAT 63 (61) 1 (1) 1 (1) 104 (100) 39 (38) 13 (18)
SPT 1 P-sIgE 1 Ara h 2 1 BAT 60 (58) 1 (1) 0 (0) 104 (100) 43 (42) 17 (119)
BAT as a second step in the
diagnostic process Correct diagnoses* No. of false positives No. of false negatives No. of BATs No. of OFCs
Change in the
no. of OFCsy
SPT/ BAT 98 (94) 3 (3) 2 (2) 24 (23) 1 (1) 235 (297)
P-sIgE/ BAT 93 (89) 5 (5) 3 (3) 41 (39) 3 (3) 233 (292)
Ara h 2/ BAT 99 (95) 2 (2) 2 (2) 19 (18) 1 (1) 235 (297)
SPT 1 P-sIgE/ BAT 97 (93) 3 (3) 1 (1) 36 (35) 3 (3) 233 (292)
SPT 1 Ara h 2/ BAT 99 (95) 2 (2) 1 (1) 38 (37) 2 (2) 234 (294)
SPT 1 P-sIgE 1 Ara h 2/ BAT 96 (92) 3 (3) 1 (1) 36 (35) 4 (4) 232 (289)
BAT as a third step in
the diagnostic process Correct diagnoses* No. of false positives No. of false negatives No. of BATs No. of OFCs
Change in the
no. of OFCsy
SPT/ Ara h 2/ BAT 98 (94) 3 (3) 3 (3) 6 (6) 0 (0) 236 (2100)
Results are presented as number of patients (% of total study population).
Ara h 2, sIgE to Ara h 2.
*The proportion of correct diagnoses was determined as (‘‘true-positives’’ 1 ‘‘true-negatives’’)/104.
Reduction in the number of OFCs was calculated in comparison with the number of OFCs after SPT and sIgE (ie, 36 OFCs, row in italic); negative numbers represent a decrease
and positive numbers an increase in the number of OFCs required.
For BAT, we used 4.78% for the average of CD631 basophils at 10 and 100 ng/mL of peanut extract as the diagnostic cutoff point.
§For BAT, excluding nonresponders, the proportion of correct diagnoses is 96.7%.
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would react clinically, we decided on clinical and ethical grounds
not to challenge them. Most of the patients who were challenged
underwent DBPCFC (48 of 61), but 4 children 1 year or younger
and another 9 older children underwent open OFCs. This is a
limitation of our study. However, most (7 of 9) of the older
children undergoing open OFCs had negative challenges (open
OFC is the gold standard for peanut tolerance) and the 2 who
had a positive OFC had objective unequivocal signs of an allergic
reaction immediately after peanut ingestion, consistent with the
new Practall guidelines’ criteria for a positiveOFC.27 In 5 patients
(4.6%), the OFCs were inconclusive, which highlights the fact
that although DBPCFC is the gold standard, it is not foolproof
in the diagnosis of peanut allergy.28 BAT may prove particularly
useful in cases in which OFC cannot be performed or is indeter-
minate. In the external validation population, 94% of the patients
were challenged and all positive OFCs were DBPCFC.
Themain limitation of BATwas the patients with nonresponder
basophils, rendering BAT uninterpretable. The proportion of
nonresponders we found (11.5% in the primary study population
and 6.2% in the external validation population) was similar to that
previously described.21,29-31 This is analogous, for example, tosituations in which SPT cannot be interpreted because of a
negative histamine control or in which P-sIgE cannot be
interpreted in the light of a high polyclonal IgE production or
indeed when an OFC is inconclusive. Importantly, these are not
misdiagnosed patients but cases in which BAT is uninterpretable
and the diagnostic workup needs to be taken further, namely, by
doing an OFC. The fact that nonresponders were almost
exclusively (92%) peanut-tolerant patients raises the question
whether basophil unresponsiveness through the IgE-mediated
pathway could be a mechanism underlying peanut tolerance.
Another limitation was that different peanut extracts were used
for different tests; however, all extracts contained the major
peanut allergens. Furthermore, our study was performed in
children recruited in a specialized clinical setting and thus may
not reflect the results of BAT to peanut in adults or the general
population. Further limitations to consider when applying BAT
in clinical practice are the fact that BAT needs to be performed
on live cells, soon after blood collection, and requires flow
cytometry equipment and appropriately trained staff.
Following the evaluation of the diagnostic performance of each
test by ROC-curve analysis, we wanted to assess their effect on
the reduction of OFCs. The effect of BAT was different in the 3
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as a sequential step in the diagnostic process (Table III). Very few
studies have addressed the utility of combinations of allergy tests,
and this deficiency has been highlighted as an unmet clinical need
in the National Institute of Allergy and Infectious Diseases–
sponsored food allergy guidelines.32 Considering single tests,
BAT performed best, followed closely by Ara h2-sIgE and SPT,
even when patients with nonresponder basophils were taken
into account. P-sIgE performed the poorest and conferred the
highest number of OFCs. Surprisingly, the different combinations
of tests provided little, if any, advantage compared with BAT
alone, with a uniform reduction in the percentage of correct
diagnoses and a significant increase in the number of OFCs
required. Disappointingly, the combination of tests did not result
in a consistent decrease in the number of false-negative outcomes.
Performing BATas a sequential step reduced the number of BATs
required (Table III and Fig E6) and had a major effect in reducing
the number of OFCs regardless of the test performed as first line.
For instance, performing BAT after SPT or after Arah2-sIgE
allowed a 97% reduction in the number of OFCs compared with
the combination of SPTand P-sIgE (our routine clinical reference
point) and a 92% reduction compared with BAT alone. However,
this was at the expense of 2 or 3 false-negative outcomes. To
prevent any false-negative cases from occurring using this
sequential test approach, we would need to challenge all the
BAT-negative patients in addition to the patients with equivocal
BAT; even in this more conservative scenario, the total number
of OFCs was significantly reduced by 64% (SPT/BAT) or
69% (Arah2-sIgE/BAT) compared with combining SPT and
P-sIgE. The decision on whether to increase the number of
OFCs or of BATs, both reducing the possibility of false-
negative tests, would depend on a cost-benefit analysis. We
believe that SPT/BAT is better than Arah2-sIgE/BAT for
practical reasons (SPT provides immediate results while
Arah2-sIgE/BAT would require 2 separate blood collections)
and given regional differences in the patterns of sensitization to
peanut allergens.13 The 3-step diagnostic strategy further reduced
the number of BATs required and eliminated the need for OFCs
but this was at the expense of a higher false-negative rate, not
from BATs but from SPTand Arah2-sIgE. For further discussion,
see this article’s Online Repository at www.jacionline.org.
To conclude, considering SPT, P-sIgE, CRD, and BAT, BAT
has the best diagnostic profile. Combinations of tests offer no
significant advantage to BAT alone and led to an increase in the
number of OFCs. The most accurate and cost-effective analysis
appears to be that of using a 2-step sequential approach in which
SPT or Arah2-sIgE is followed by BAT in equivocal cases. To
maximize safety and decrease false-negative tests to 0%, the
2-step sequential approach can be modified to do OFCs in the
cases with equivocal BATas well as in BAT-negative patients. We
should bear in mind the limitations of OFC (3% false-negative28
and 2%-9% indeterminate outcomes33,34). Future studies will
determine whether BAT can add to the OFC as an in vitro gold
standard.
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Clinical implications: The basophil activation test to peanut can
be performed in cases inwhich standard allergy tests have failed
to diagnose peanut allergy before considering oral food
challenges.REFERENCES
1. Branum AM, Lukacs SL. Food allergy among children in the United States.
Pediatrics 2009;124:1549-55.
2. Sicherer SH, Munoz-Furlong A, Godbold JH, Sampson HA. US prevalence of
self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy
Clin Immunol 2010;125:1322-6.
3. Perry TT, Matsui EC, Conover-Walker MK, Wood RA. Risk of oral food
challenges. J Allergy Clin Immunol 2004;114:1164-8.
4. Sicherer SH, Wood RA. Advances in diagnosing peanut allergy. J Allergy Clin
Immunol Pract 2013;1:1-13.
5. Sampson HA, Ho DG. Relationship between food-specific IgE concentrations
and the risk of positive food challenges in children and adolescents. J Allergy
Clin Immunol 1997;100:444-51.
6. Sampson HA. Utility of food-specific IgE concentrations in predicting
symptomatic food allergy. J Allergy Clin Immunol 2001;107:891-6.
7. Rance F, Abbal M, Lauwers-Cances V. Improved screening for peanut allergy by
the combined use of skin prick tests and specific IgE assays. J Allergy Clin
Immunol 2002;109:1027-33.
8. Roberts G, Lack G. Diagnosing peanut allergy with skin prick and specific IgE
testing. J Allergy Clin Immunol 2005;115:1291-6.
9. van Nieuwaal NH, Lasfar W, Meijer Y, Kentie PA, Flinterman AE, Pasmans SG,
et al. Utility of peanut-specific IgE levels in predicting the outcome of double-
blind, placebo-controlled food challenges. J Allergy Clin Immunol 2010;125:
1391-2.
10. Roberts G, Lack G. Food allergy–getting more out of your skin prick tests.
Clin Exp Allergy 2000;30:1495-8.
11. Nicolaou N, Murray C, Belgrave D, Poorafshar M, Simpson A, Custovic A.
Quantification of specific IgE to whole peanut extract and peanut components in
prediction of peanut allergy. J Allergy Clin Immunol 2011;127:684-5.
12. Dang TD, Tang M, Choo S, Licciardi PV, Koplin JJ, Martin PE, et al. Increasing
the accuracy of peanut allergy diagnosis by using Ara h 2. J Allergy Clin Immunol
2012;129:1056-63.
13. Vereda A, van Hage M, Ahlstedt S, Ibanez MD, Cuesta-Herranz J, van
Odijk J, et al. Peanut allergy: clinical and immunologic differences among
patients from 3 different geographic regions. J Allergy Clin Immunol 2011;
127:603-7.
14. Lieberman JA, Glaumann S, Batelson S, Borres MP, Sampson HA, Nilsson
C. The utility of peanut components in the diagnosis of IgE-mediated peanut
allergy among distinct populations. J Allergy Clin Immunol Pract 2013;1:
75-82.
15. Ebo DG, Bridts CH, Hagendorens MM, Aerts NE, De Clerck LS, Stevens WJ.
Basophil activation test by flow cytometry: present and future applications in
allergology. Cytometry B Clin Cytom 2008;74:201-10.
16. Chirumbolo S, Vella A, Ortolani R, De Gironcoli M, Solero P, Tridente G, et al.
Differential response of human basophil activation markers: a multi-parameter
flow cytometry approach. Clin Mol Allergy 2008;6:12.
17. Fox AT, Sasieni P, du Toit G, Syed H, Lack G. Household peanut consumption as a
risk factor for the development of peanut allergy. J Allergy Clin Immunol 2009;
123:417-23.
18. Du Toit G, Roberts G, Sayre PH, Plaut M, Bahnson HT, Mitchell H, et al.
Identifying infants at high risk of peanut allergy: the Learning Early About
Peanut Allergy (LEAP) screening study. J Allergy Clin Immunol 2013;131:
135-43, e1-12.
19. Marrs T, Du Toit G, Fox AT, Perkin M, Lack G. Double-blind food challenges can
be conducted effectively by using interspersed active and placebo doses among
children. J Allergy Clin Immunol 2013;132:502.
20. Brough HA, Makinson K, Penagos M, Maleki SJ, Cheng H, Douiri A, et al.
Distribution of peanut protein in the home environment. J Allergy Clin Immunol
2013;132:623-9.
21. Ocmant A, Mulier S, Hanssens L, Goldman M, Casimir G, Mascart F, et al.
Basophil activation tests for the diagnosis of food allergy in children. Clin Exp
Allergy 2009;39:1234-45.
J ALLERGY CLIN IMMUNOL
SEPTEMBER 2014
652 SANTOS ET AL22. Poggio T, Rifkin R, Mukherjee S, Niyogi P. General conditions for predictivity in
learning theory. Nature 2004;428:419-22.
23. Zhou XH, Qin G. Improved confidence intervals for the sensitivity at a fixed level
of specificity of a continuous-scale diagnostic test. Stat Med 2005;24:465-77.
24. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic.
Fam Med 2005;37:360-3.
25. Glaumann S, Nopp A, Johansson SG, Rudengren M, Borres MP, Nilsson C.
Basophil allergen threshold sensitivity, CD-sens, IgE-sensitization and DBPCFC
in peanut-sensitized children. Allergy 2012;67:242-7.
26. Javaloyes G, Goikoetxea MJ, Garcia Nunez I, Sanz ML, Blanca M, Scheurer S,
et al. Performance of different in vitro techniques in the molecular diagnosis of
peanut allergy. J Investig Allergol Clin Immunol 2012;22:508-13.
27. Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, Sicherer S, Teuber SS,
Burks AW, et al. Standardizing double-blind, placebo-controlled oral food
challenges: American Academy of Allergy, Asthma & Immunology-European
Academy of Allergy and Clinical Immunology PRACTALL consensus report.
J Allergy Clin Immunol 2012;130:1260-74.
28. Caffarelli C, Petroccione T. False-negative food challenges in children with
suspected food allergy. Lancet 2001;358:1871-2.29. Rubio A, Vivinus-Nebot M, Bourrier T, Saggio B, Albertini M, Bernard A. Benefit
of the basophil activation test in deciding when to reintroduce cow’s milk in
allergic children. Allergy 2011;66:92-100.
30. Ebo DG, Hagendorens MM, Bridts CH, Schuerwegh AJ, De Clerck LS, Stevens WJ.
Flow cytometric analysis of in vitro activated basophils, specific IgE and skin tests in
thediagnosisofpollen-associated foodallergy.CytometryBClinCytom2005;64:28-33.
31. Ford LS, Bloom KA, Nowak-Wegrzyn AH, Shreffler WG, Masilamani M, Samp-
son HA. Basophil reactivity, wheal size, and immunoglobulin levels distinguish
degrees of cow’s milk tolerance. J Allergy Clin Immunol 2013;131:180-6.e3.
32. Boyce JA, Assa’ad A, Burks AW, Jones SM, Sampson HA, Wood RA, et al. Guide-
lines for the diagnosis and management of food allergy in the United States: report
of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010;126:S1-58.
33. Ludman S, Ballabeni P, Eigenmann PA, Wassenberg J. Predicting positive food
challenges in children sensitised to peanuts/tree nuts. Pediatr Allergy Immunol
2013;24:276-81.
34. Nolan RC, Richmond P, Prescott SL, Mallon DF, Gong G, Franzmann AM, et al.
Skin prick testing predicts peanut challenge outcome in previously allergic or
sensitized children with low serum peanut-specific IgE antibody concentration.
Pediatr Allergy Immunol 2007;18:224-30.
